3 terminated. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
| Phase 2 | 2 | Terminated 2 |
Follow melflufen: new trials by email Literature Review of melflufen trials Research Report on melflufen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis Melphalan-Flufenamide (Melflufen), Dexamethasone - AL Amyloidosis | Phase 1 | Terminated | Oncopeptides AB | 6 | 2020-08-06 | 2022-03-28 |
| Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Oncopeptides AB | 56 | 2018-04-12 | 2022-12-19 |
| Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients Melflufen, Dexamethasone - Relapsed and/or Relapsed-refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Oncopeptides AB | 75 | 2013-07-01 | 2020-10-23 |
Immunoglobulin Light-chain Amyloidosis (1) · Multiple Myeloma (1)
Oncopeptides AB (3)
United States (3) · Czechia (2) · France (2) · Spain (2) · Denmark (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Netherlands (1) · Norway (1) · Sweden (1) · United Kingdom (1)
Giovanni Palladini, MD (1) · Johan Harmenberg, MD (1) · Paul G Richardson, MD (1)